孕激素与他莫西芬合用降低子宫内膜癌的风险

Role of progestogen in decreasing risk of tamoxifen-associated malignant endometrial carcinoma

他莫西芬由于其本身的优势仍是激素依赖型转移性乳腺癌的一线治疗用药,也是雌激素受体阳性、原发性早期乳腺癌术后辅助内分泌治疗的首选药物。乳腺癌患者在长时间服用他莫西芬后,可增加发生子宫内膜癌的危险性。孕激素不仅可以治疗乳腺癌,而且在口服避孕药、雌孕激素替代疗法中,孕激素有保护子宫内膜的作用。该文意在探讨长期口服他莫西芬治疗的乳腺癌患者加服小剂量孕激素降低子宫内膜异常的风险。

Because of unique mechanism and intrinsic advantages, tamoxifen is still the first choice in hormonotherapy for hormone- dependent metastasized breast cancer. It is also a first-chosen drug in postoperative adjuvant endocrinotherapy of primary early breast cancer in situ with positive estrogen receptor （ER）. Epidemiological data and clinical trials have confirmed that long-term oral administration of tamoxifen increases risk of endometrial carcinoma. While progestogen used in oral contraceptives （OCs） or HRT not only can treat breast cancer but also has protective effect on endometria from developing endometrial carcinoma. This article explored mechanisms that low dose of progestogen decreases risk of tamoxifen-associated endometrial carcinoma of those women with breast cancer who orally took tamoxifen for a long.